|
시장보고서
상품코드
2038963
신경학 의약품 시장 : 질환별, 약제 클래스별, 투여 경로별, 유통 채널별, 지역별Neurology Drugs Market, By Disease Type, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
신경학 의약품 시장은 2026년에 740억 달러로 추계되고 있으며, 2033년까지 1,040억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 4.98%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 740억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 4.98% | 2033년 시장 규모 예측 : | 1,040억 달러 |
세계의 신경계 치료제 시장은 중추신경계와 말초신경계에 영향을 미치는 복잡한 질환에 대응하는 제약업계의 중요한 부문으로, 그 대상 범위는 중추신경계와 말초신경계에 영향을 미치는 복잡한 질환에 대한 대응입니다.
신경계 의약품에는 간질, 알츠하이머병, 파킨슨병, 다발성 경화증, 편두통, 뇌졸중 등 다양한 질환의 치료제가 포함됩니다. 신경계 의약품 시장의 성장은 주로 신경질환의 유병률 증가, 고령화 진행, 신경 생물학적 메커니즘에 대한 이해의 심화에 의해 주도되고 있습니다. 특히 선진국과 신흥 국가의 신경질환 유병률 증가는 신경계 의약품 시장 성장의 주요 촉진요인으로 작용하고 있습니다.
한편, 제약사들의 연구개발 활동도 활발해지면서 약물전달, 맞춤형 의료 및 다양한 질병에 대한 새로운 치료법 등의 도입이 진행되고 있습니다. 신경질환 치료는 복잡한 위험 프로파일을 수반하므로 시장은 엄격한 규제를 받고 있으며, 임상적 검증이 요구되고 있습니다. 특허 만료, 제네릭 의약품, 헬스케어 인프라 변화, 임상 가이드라인 변경 등의 주요 요인도 이 시장의 중요한 성장 요인으로 작용하고 있습니다. 또한 유전자치료, 면역치료, 정밀의료가 현재의 치료 방식을 바꾸고 있으며, 이는 질병 관리에 새로운 기회를 가져다주고 있습니다.
시장 역학
세계의 신경계 의약품 시장은 인구 통계, 기술, 헬스케어와 관련된 다양한 요인에 의해 주도되고 있습니다. 고령화에 따라 치매, 파킨슨병, 간질 등 신경계 질환이 증가하고 있는 것이 신경계 의약품 시장 성장에 기여하고 있습니다. 신약개발의 인공지능 활용, 바이오마커 발굴, 정밀의학 적용 등 신약개발 기술의 발전도 성장을 촉진하고 있습니다. 또한 헬스케어 비용의 증가, 진단 기술의 향상, 신흥 시장의 의료 인프라 확충도 신경계 의약품 시장의 성장에 기여하고 있습니다.
하지만, 이 시장에는 몇 가지 과제도 존재합니다. 특히 높은 연구개발 비용과 규제 당국의 승인 획득 등이 신규 진입 기업에게 장벽으로 작용하고 있습니다. 또한 블록버스터 의약품의 특허만료로 인해 제네릭 의약품 부문의 경쟁환경이 심화되고 있으며, 이는 각 기업의 매출에 영향을 미치고 있습니다. 임상 시험의 어려움, 윤리적 문제, 후기 단계 의약품 개발의 높은 실패율은 이 시장의 또 다른 도전 과제입니다. 또한 안전성에 대한 문제나 부작용의 발생도 있으며, 이 시장에서는 감시체계가 필수적입니다.
이러한 도전과제가 있는 반면, 이 시장에는 많은 기회가 존재합니다. 특히 의료 인프라 및 의료관광 측면에서 성장하고 있는 개발도상국의 신흥 시장에서는 이러한 경향이 두드러집니다. 희귀질환 치료제, 디지털 치료제, 병용요법, 신경질환 치료제, 약물전달 시스템 등이 이 시장의 미래 성장 기회로 꼽힙니다.
본 조사의 주요 특징
- 이 보고서는 다양한 부문의 잠재적 매출 창출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 연구는 다음과 같은 매개 변수를 기반으로 세계의 신경계 치료제 시장의 주요 기업 개요을 작성했습니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계의 신경계 의약품 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 글로벌 신경계 의약품 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 신경학 의약품 시장 : 질환별, 2021-2033년
제5장 세계의 신경학 의약품 시장 : 약제 클래스별, 2021-2033년
제6장 세계의 신경학 의약품 시장 : 투여 경로별, 2021-2033년
제7장 세계의 신경학 의약품 시장 : 유통 채널별, 2021-2033년
제8장 세계의 신경학 의약품 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 애널리스트의 추천
제11장 참고 문헌 및 조사 방법
KSA 26.06.02Neurology Drugs Market is estimated to be valued at USD 74 Bn in 2026 and is expected to reach USD 104 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.98% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 74 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.98% | 2033 Value Projection: | USD 104 Bn |
The global neurology drugs market is an important segment of the pharmaceutical industry, and its scope is to address complex diseases affecting the central and peripheral nervous systems.
Neurology drugs include treatments for various diseases, such as epilepsy, Alzheimer's, Parkinson's, multiple sclerosis, migraine, stroke, and many more. The growth of the neurology drugs market is mainly propelled by an increase in the prevalence of neurological disorders, rising aging population, and an increased understanding of neurobiological mechanisms. The increased prevalence of neurological diseases, particularly in developed and emerging countries, is a key driver of the growth of the neurology drugs market.
On the other hand, there are increased R&D activities by companies to introduce new therapies such as drug delivery systems, personalization of medicine, and new therapies for different conditions. The market is highly regulated, with clinical validation due to a complex risk profile associated with therapies for neurological conditions. Major factors such as patent expiration, generics, changes in healthcare infrastructure, and changes in clinical guidelines are other key drivers for this market. Furthermore, gene therapy, immunotherapy, and precision medicine are changing the current therapy landscape, thus providing new opportunities for the management of this condition.
Market Dynamics
The global neurology drugs market is fueled by various factors related to demography, technology, and healthcare. Growing cases of dementia, Parkinson's disease, and epilepsy among the aging population contribute to the growth of the neurology drugs market. Improvements in drug discovery techniques, including the application of artificial intelligence in drug discovery, the identification of biomarkers, and the application of precision medicine, further propels the growth. Additionally, increasing healthcare expenditure, improvements in diagnostic techniques, and the expansion of the healthcare infrastructure in emerging markets also contribute to the growth of the neurology drugs market.
However, there are certain challenges in this market, which include high R&D costs and regulatory approvals, which act as a restraint in this market for new entrants. The expiration of patents on blockbuster drugs creates a competitive environment in the generics segment, which affects the revenue received by these companies. Challenges in clinical trials, ethical issues, and high failure rates in late-stage drug development are other issues in this market. In addition, there are safety issues and the occurrence of adverse effects, which necessitate surveillance in this market.
Despite the challenges, there are many opportunities in this market, especially in the new markets of developing nations, which are growing in terms of healthcare infrastructure and medical tourism. Orphan drugs for neurological disorders, digital therapeutics, combination therapies, and drug delivery systems are opportunities in this market for future growth.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global neurology drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include F. Hoffmann-La Roche, Johnson & Johnson, AbbVie, Merck & Co., Teva Pharmaceutical Industries, Eisai, H. Lundbeck, UCB, Otsuka Pharmaceutical, and Jazz Pharmaceuticals
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global neurology drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neurology drugs market
Market Segmentation
- Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
- Alzheimer's Disease
- Parkinson's Disease
- Epilepsy
- Multiple Sclerosis
- Migraine
- Huntington's Disease
- Others
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Antiepileptics
- Antipsychotics
- Dopamine Agonists
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Analgesics (Migraine-specific)
- Others
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Injectable
- Transdermal
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- F. Hoffmann-La Roche
- Johnson & Johnson
- AbbVie
- Merck & Co.
- Teva Pharmaceutical Industries
- Eisai
- Lundbeck
- UCB
- Otsuka Pharmaceutical
- Jazz Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Neurology Drugs Market, By Disease Type
- Global Neurology Drugs Market, By Drug Class
- Global Neurology Drugs Market, By Route of Administration
- Global Neurology Drugs Market, By Distribution Channel
- Global Neurology Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trends
4. Global Neurology Drugs Market, By Disease Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Alzheimer's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Parkinson's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Epilepsy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Multiple Sclerosis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Migraine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Huntington's Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Neurology Drugs Market, By Drug Class, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Antiepileptics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Dopamine Agonists
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cholinesterase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- NMDA Receptor Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Analgesics (Migraine-specific)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Neurology Drugs Market, By Route of Administration, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Transdermal
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
7. Global Neurology Drugs Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
8. Global Neurology Drugs Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- F. Hoffmann-La Roche
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eisai
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Jazz Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
